Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 4
2010 6
2011 9
2012 8
2013 8
2014 6
2015 3
2016 6
2017 5
2018 5
2019 10
2020 13
2021 9
2022 15
2023 15
2024 24
2025 28
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Harada-Shiba M, Curcio DL, Neild A, Kling D, Hsieh A, Butters J, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Huo Y, Szarek M, Balinskaite V, Davidson MH; BROADWAY Investigators. Nicholls SJ, et al. Among authors: nelson aj. N Engl J Med. 2025 Jul 3;393(1):51-61. doi: 10.1056/NEJMoa2415820. Epub 2025 May 7. N Engl J Med. 2025. PMID: 40337982 Clinical Trial.
The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events. METHODS: We conducted a multinational, randomized, placebo-controlled trial involving patients with heterozygous familial hypercholesterolemia or …
The efficacy and safety of obicetrapib have not been fully characterized among patients at high risk for cardiovascular events. METHO …
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
Ostrominski JW, Cheng AYY, Nelson AJ, Neuen BL, Sattar N, Tuttle KR, Vaduganathan M. Ostrominski JW, et al. Among authors: nelson aj. Lancet. 2025 Sep 13;406(10508):1171-1192. doi: 10.1016/S0140-6736(25)01384-4. Epub 2025 Aug 29. Lancet. 2025. PMID: 40889511 Review.
Epidemiological studies have indicated that other forms of cardiovascular disease, along with kidney and metabolic dysfunction, frequently and increasingly contribute to heart failure onset. Clinical trials have additionally demonstrated the power of several new pharmacoth …
Epidemiological studies have indicated that other forms of cardiovascular disease, along with kidney and metabolic dysfunction, frequ …
Managing hypercholesterolaemia.
Nelson AJ, Nicholls SJ. Nelson AJ, et al. Aust Prescr. 2024 Feb;47(1):7-14. doi: 10.18773/austprescr.2024.006. Aust Prescr. 2024. PMID: 38444897 Free PMC article. Review.
Low-density lipoprotein cholesterol (LDL-C) plays a causal role in the development and progression of atherosclerosis and cardiovascular disease. Every 1 mmol/L reduction in LDL-C concentration is associated with a 21 to 25% reduction in the relative risk of prospective at …
Low-density lipoprotein cholesterol (LDL-C) plays a causal role in the development and progression of atherosclerosis and cardiovascular …
Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.
Kelsey MD, Nelson AJ, Green JB, Granger CB, Peterson ED, McGuire DK, Pagidipati NJ. Kelsey MD, et al. Among authors: nelson aj. J Am Coll Cardiol. 2022 May 10;79(18):1849-1857. doi: 10.1016/j.jacc.2022.02.046. J Am Coll Cardiol. 2022. PMID: 35512864 Free PMC article. Review.
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. ...There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the …
Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. ...There are sever …
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
Pagidipati NJ, Nelson AJ, Kaltenbach LA, Leyva M, McGuire DK, Pop-Busui R, Cavender MA, Aroda VR, Magwire ML, Richardson CR, Lingvay I, Kirk JK, Al-Khalidi HR, Webb L, Gaynor T, Pak J, Senyucel C, Lopes RD, Green JB, Granger CB; COORDINATE–Diabetes Site Investigators. Pagidipati NJ, et al. Among authors: nelson aj. JAMA. 2023 Apr 18;329(15):1261-1270. doi: 10.1001/jama.2023.2854. JAMA. 2023. PMID: 36877177 Free PMC article. Clinical Trial.
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. ...CONCLUSIONS AND RELEVANCE: A coordinated, multifaceted intervention increased prescription of 3 groups of eviden …
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underus …
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Goldberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh A, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Nicholls SJ, et al. Among authors: nelson aj. Am Heart J. 2024 Aug;274:32-45. doi: 10.1016/j.ahj.2024.05.002. Epub 2024 May 4. Am Heart J. 2024. PMID: 38705341 Free article.
By substantially reducing LDL-C, obicetrapib has the potential to lower atherogenic lipoproteins in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels remain high despite treatment with avail …
By substantially reducing LDL-C, obicetrapib has the potential to lower atherogenic lipoproteins in patients with atherosclerotic cardiov …
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH; PRONOUNCE Study Investigators. Lopes RD, et al. Among authors: nelson aj. Circulation. 2021 Oct 19;144(16):1295-1307. doi: 10.1161/CIRCULATIONAHA.121.056810. Epub 2021 Aug 30. Circulation. 2021. PMID: 34459214 Free PMC article. Clinical Trial.
BACKGROUND: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. ...CONCLUSIONS: PRONOUNCE (A Trial Com …
BACKGROUND: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in me …
Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ, Nelson AJ, Lincoff AM, Brennan D, Ray KK, Cho L, Menon V, Li N, Bloedon L, Nissen SE. Nicholls SJ, et al. Among authors: nelson aj. JAMA Cardiol. 2024 Mar 1;9(3):245-253. doi: 10.1001/jamacardio.2023.5155. JAMA Cardiol. 2024. PMID: 38231501 Free PMC article. Clinical Trial.
The key secondary end point was time to first event for cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MACE-3). This prespecified analysis compared the total number of cardiovascular events in the treatment groups. ...CONCLUSION AND RELEV …
The key secondary end point was time to first event for cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MA …
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, Hsieh A, Szarek M, Kastelein JJ, Davidson MH. Nicholls SJ, et al. Among authors: nelson aj. J Am Coll Cardiol. 2025 Oct 7;86(14):1046-1056. doi: 10.1016/j.jacc.2025.07.056. Epub 2025 Sep 1. J Am Coll Cardiol. 2025. PMID: 40888776 Free article.
OBJECTIVES: In this study, we sought to determine the effect of obicetrapib on cardiovascular events. METHODS: The effects of 10 mg obicetrapib and placebo daily on major adverse cardiovascular event (MACE) rates were investigated in a pooled analysis of 354 patient …
OBJECTIVES: In this study, we sought to determine the effect of obicetrapib on cardiovascular events. METHODS: The effects of 10 mg o …
Oral agents for lowering lipoprotein(a).
Nicholls SJ, Nelson AJ, Michael LF. Nicholls SJ, et al. Among authors: nelson aj. Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25. Curr Opin Lipidol. 2024. PMID: 39329200 Review.
Ongoing clinical trials will evaluate the impact of muvalaplin in high cardiovascular risk and will ultimately need to determine whether this strategy lowers the rate of cardiovascular events. ...The ability of muvalaplin to reduce cardiovascular risk remains …
Ongoing clinical trials will evaluate the impact of muvalaplin in high cardiovascular risk and will ultimately need to determine whet …
173 results